#nasdaq:ilmn

[managermint]

InvestorPlace: 4 Top Stock Trades for Monday:JNJ, SQ, ILMN, ACB

InvestorPlace: 4 Top Stock Trades for Monday:JNJ, SQ, ILMN, ACB

The stock market is slowly but surely pushing higher. It seems as though the bulls are reluctant to run too far, too fast. At the same time, the bears simply can’t garner any staying power when it comes to pushing this market lower. At least not while rate cuts are on the way. Let’s look at a few top stock trades for next week.

Top Stock Trades for Monday #1: Johnson & Johnson

Click to Enlarge

S…

View On WordPress

[marketexclusive]

AstraZeneca Plc (ADR) (NYSE:AZN) Latest Initiative To House 2 Million Genomes

AstraZeneca plc (ADR) (NYSE:AZN) has announced a new initiative to to house 2 million genome sequences aimed at gathering information that will facilitate the advancement of drug discovery and development. To achieve this, the company will set up a dedicated center for the research which will feature all the genes required to make and operate an organism.

Click Here For More Market Exclusive Updates & Analysis

Genome sequence data from clinical samples will be put together while the center will allow access of up to the available 500,000 genomes. The clinical samples will be analyzed using various analytical techniques likes machine learning and pattern recognition. Whole genome sequencing will be carried out on everything in the database and AstraZeneca is optimistic on being able to gather at least 5 petabytes of data in total, or 5,000 terabytes.

The project will have a price tag in the hundreds of millions of dollars and will involve the Wellcome Trust Sanger Institute as reported by AstraZeneca EVP Mene Pangalos. Some of the cash will benefit Human Longevity, Inc, the J. Craig Venter founded sequencing shop which is one the organizations that carries out such projects.

Close to 500,000 samples will be sent to Human Longevity for sampling. That means Venter’s suite of Illumina, Inc. (NASDAQ:ILMN) HiSeq X sequencers will have to process plenty of material.

According to Pangalos, early development of innovative medicines is of the essence. He confirms that it is for this reason that the company will embrace the use of the power of genomics as the foundation of the company’s ambition.  The company will be able to access the fast-growing Human Longevity’s database.

With a wide range of initiatives, AstraZeneca is laying a bet that this new one will help in the identification of rare genetic variants with the increase of the size of the genome repository.

AstraZeneca Plc (ADR) (NYSE:AZN) Latest Initiative To House 2 Million Genomes was originally published on Market Exclusive

[marketexclusive]

Gilead Sciences, Inc. (NASDAQ:GILD) Commits To Expand To Foster City

Gilead Sciences, Inc. (NASDAQ:GILD) has so far been able to make tens of billions of dollars from its two new hep C pills and in celebration of its hard work, it intends to expand into its 71-acre corporate campus in its native city and from where it shall offer new labs.

 According to a city Planning Commission the company’s plans is to knock down an existing single-story building an instead build a six-story lab and office building. Apparently, Gilead has already purchased a $120 million 12-acre Chess-Hatch office complex which it anticipates to revamp into nearly 800,000 square feet of building space. However, it is still working on the compliance of plans that will give a go ahead to the redevelopment.

The Foster City, CA-headquartered company has continued to propel in its business growth an according to a spokeswoman, it is always evaluation needs that facilitate expansion. Its main mission is to deliver life-saving medicines to patients worldwide.

The company hit a jack pot of fortune through its blockbuster suite of HIV drugs. The fortune became bigger and better after the endorsement of its Harvoni and Sovaldi for hepatitis C and the two have transformed the way hep C is cured. The annual sales went up from $24.9 billion in 2014 to $32.6 billion in 2015 which clearly explains how the fortune came about. The current market cap stands at $130.8 billion which indicates that the company is going places.

The upcoming plans are a means of maintaining the company’s presence in Foster City. The Bay Area has already made a mark by being a center of excellence for the biopharmaceutical industry. And with the rising competition in the industry other companies the likes of Illumina, Inc. (NASDAQ:ILMN) are also seeking a market share of the Bay Area and will soon be erecting a $149 million biotech campus on a more than 20-acre site.

 But on close scrutiny Gilead has declined to divulge any information as to whether it is planning any major M&A deals. Already the company has obtained an early-stage NASH from the MA-based biotech Nimbus Therapeutics for $1.2 billion.

Gilead Sciences, Inc. (NASDAQ:GILD) Commits To Expand To Foster City was originally published on Market Exclusive

[stockmarketsdaily]

New Post has been published on Stock Markets Daily

New Post has been published on http://www.stockmarketsdaily.com/value-check-big-gainers-illumina-ilmn-korea-electric-power-kep-super-micro-computer-smci/7180/

Value Check of Big Gainers: Illumina (ILMN), Korea Electric Power (KEP), Super Micro Computer (SMCI)

(adsbygoogle = window.adsbygoogle || []).push();

We look at Illumina Inc (NASDAQ:ILMN), Korea Electric Power Corp (NYSE:KEP), and Super Micro Computer Inc (NASDAQ:SMCI), 3 companies getting a lot of attention at the moment, to assess which may provide the best value for investors to consider buying and which are over, under or fairly priced.

Rather than the usual Price to Earnings (P/E) multiple method, we feel the best way to assess which of Illumina (ILMN), Korea Electric Power (KEP), Super Micro Computer (SMCI) is the best value currently is to use the PEG ratio (P/E to growth). This PEG multiple takes into account the expected long term growth in earnings of the companies rather than merely the growth for one earnings period ahead as forward P/E does.

As a rule of thumb, a stock with a PEG of between 0 and 1 is usually considered to be underpriced, between 1 and 2 to be at fair value and over 2 to be overpriced.

Illumina (NASDAQ:ILMN) had a last closing stock price of $196.73 after moving 7.02% in trading with a trailing 12 month P/E multiple of 103.00 and an estimated forward P/E multiple of 61.94. Illumina (ILMN) has an estimated 5 year annual growth of 25.03% and a PEG multiple of 4.12. Based on the PEG ratio of ILMN being 4.12, we consider Illumina to likely be overpriced. [Trend Analysis]

Korea Electric Power (NYSE:KEP) had a last closing stock price of $19.30 after moving 5.70% in trading with a trailing 12 month P/E multiple of 11.63 and an estimated forward P/E multiple of 2.68. Korea Electric Power (KEP) has an estimated 5 year annual growth of 25.00% and a PEG multiple of 0.47. Based on the PEG ratio of KEP being 0.47, we consider Korea Electric Power to likely be underpriced. [Trend Analysis]

Super Micro Computer (NASDAQ:SMCI) had a last closing stock price of $37.74 after moving 7.61% in trading with a trailing 12 month P/E multiple of 27.15 and an estimated forward P/E multiple of 18.66. Super Micro Computer (SMCI) has an estimated 5 year annual growth of 15.00% and a PEG multiple of 1.81. Based on the PEG ratio of SMCI being 1.81, we consider Super Micro Computer to likely be at fair value. [Trend Analysis]

Based on the above, it would appear that Korea Electric Power offers the best value, as it has the lowest PEG ratio of 0.47, when compared to the other stocks. This makes it appear less expensive due to having a lower stock price against current earnings and predicted growth in those earnings in the coming 5 years.

However, on an individual stock basis, the analysis concludes that Illumina (NASDAQ:ILMN) is overpriced, Korea Electric Power (NYSE:KEP) is underpriced and Super Micro Computer (NASDAQ:SMCI) is at fair value.